Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin.
about
HEXIM2, a HEXIM1-related protein, regulates positive transcription elongation factor b through association with 7SKIMP dehydrogenase type 1 associates with polyribosomes translating rhodopsin mRNAFinding disease-related genomic experiments within an international repository: first steps in translational bioinformaticsNSPc1 is a cell growth regulator that acts as a transcriptional repressor of p21Waf1/Cip1 via the RARE elementAccounting for noise when clustering biological data.Reversing chromatin accessibility differences that distinguish homologous mitotic metaphase chromosomes.Role of SUMO:SIM-mediated protein-protein interaction in non-homologous end joining.A gene-rich, transcriptionally active environment and the pre-deposition of repressive marks are predictive of susceptibility to KRAB/KAP1-mediated silencing.The classification of mRNA expression levels by the phosphorylation state of RNAPII CTD based on a combined genome-wide approach.An SF1 affinity model to identify branch point sequences in human introns.Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expressionNoxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.Chromatin modification by SUMO-1 stimulates the promoters of translation machinery genes.Promoters active in interphase are bookmarked during mitosis by ubiquitination.Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.Topoisomerases facilitate transcription of long genes linked to autismCreation and implications of a phenome-genome network
P2860
Q24294998-4D0C69EC-70C9-4CF1-86F2-5AC2D5FA6FECQ24643480-23DFA3D4-94A0-4035-99B9-B23395010A86Q24673036-2B8A182C-23AE-46E8-8D90-C19A36F55A68Q24674566-442DFC69-3640-4478-8FA1-A3536D180448Q30573304-99B3FB52-7564-45D1-9801-2151DB236357Q30660924-CD17F3FB-5A2C-426B-A8D3-0A54A2629E83Q33940026-D7FDBD5D-1485-4A4E-8FA4-B0E3C516DAEEQ33972163-C53F2648-389E-4968-A3B1-2B16DB88E473Q34051550-D2872BAD-7F46-4993-BE99-343C9C7C43F6Q34723469-580C56B9-230B-4AE2-871E-146EF61B4A84Q35614104-963F6223-9B03-4501-9F0B-2FC1233D4EACQ36088654-EFF46BE1-1818-4290-B896-03D601A4B3A1Q36108221-12496AE1-56AC-4E61-B457-0F0E01AB99C9Q36368843-5A7DE034-4C07-45D2-AA1D-EAC366FB8183Q36368847-D19B429C-7739-4840-A423-52BC80D1A114Q36916118-1721415B-62E0-49BC-A150-E87B9BAEB46BQ37156727-B3C1DDB4-BAD1-4D36-B650-22D17C9135C1Q37276752-F90933DA-EF4D-4E7B-97BF-87B540523CF3
P2860
Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacogenomic identification ...... isomerase poison camptothecin.
@en
Pharmacogenomic identification ...... isomerase poison camptothecin.
@nl
type
label
Pharmacogenomic identification ...... isomerase poison camptothecin.
@en
Pharmacogenomic identification ...... isomerase poison camptothecin.
@nl
prefLabel
Pharmacogenomic identification ...... isomerase poison camptothecin.
@en
Pharmacogenomic identification ...... isomerase poison camptothecin.
@nl
P2093
P1433
P1476
Pharmacogenomic identification ...... isomerase poison camptothecin.
@en
P2093
Garrett M Frampton
Jonathan P Carson
Marc E Lenburg
Michael F Christman
Nianyi Zhang
Norman P Gerry
P304
P356
10.1158/0008-5472.CAN-03-2029
P407
P577
2004-03-01T00:00:00Z